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AbsTrACT
background the currently known breast cancer-
associated single nucleotide polymorphisms (SnPs) are 
presently not used to guide clinical management. We 
explored whether a genetic test that incorporates a SnP-
based polygenic risk score (PrS) is clinically meaningful 
in non-BRCA1/2 high-risk breast cancer families.
Methods 101 non-BRCA1/2 high-risk breast cancer 
families were included; 323 cases and 262 unaffected 
female relatives were genotyped. the 161-SnP PrS was 
calculated and standardised to 327 population controls 
(sPrS). association analysis was performed using a 
cox-type random effect regression model adjusted by 
family history. Updated individualised breast cancer 
lifetime risk scores were derived by combining the Breast 
and Ovarian analysis of Disease incidence and carrier 
estimation algorithm breast cancer lifetime risk with the 
effect of the sPrS.
results the mean sPrS for cases and their unaffected 
relatives was 0.70 (SD=0.9) and 0.53 (SD=0.9), 
respectively. a significant association was found between 
sPrS and breast cancer, Hr=1.16, 95% ci 1.03 to 
1.28, p=0.026. addition of the sPrS to risk prediction 
based on family history alone changed screening 
recommendations in 11.5%, 14.7% and 19.8 % of the 
women according to breast screening guidelines from 
the USa (national comprehensive cancer network), UK 
(national institute for Health and care excellence and 
the netherlands (netherlands comprehensive cancer 
Organisation), respectively.
Conclusion Our results support the application of 
the PrS in risk prediction and clinical management of 
women from genetically unexplained breast cancer 
families.
InTroduCTIon
Breast cancer is the most common cancer in women 
in the Western world. For women with a first-degree 
relative with breast cancer, the risk for developing 
breast cancer is twofold in comparison with women 
without such a family history.1 Approximately 20% 
of this familial relative risk is explained by patho-
genic variants in the high-risk genes BRCA1 and 
BRCA2, 2%–5% by variants in other breast cancer 
genes (eg, CHEK2, PALB2 and ATM) and 18% by 
the currently known common low risk variants, 
mostly single nucleotide polymorphisms (SNPs).2–5
Individually, these SNPs confer a very small 
increase in breast cancer risk but jointly they may 
confer a substantial increase of the risk.2 This 
combined risk of all SNPs associated with breast 
cancer can be summarised in a polygenic risk score 
(PRS). The PRS can stratify women into different 
risk categories,2 6–8 which for 8% of women from 
the general population might be high enough to be 
clinically relevant, regardless of family history.2
The PRS may also be combined with other risk 
factors, such as BRCA1/2 status or breast cancer 
family history, to further refine and individualise 
risk estimation. The large majority of breast cancer 
families seen in Family Cancer Clinics today cannot 
be linked to pathogenic variants in BRCA1 or 
BRCA2. Risk management for women from these 
families is based mainly on family history, which 
can be used as a variable to calculate individual 
breast cancer risk in various risk prediction algo-
rithms,9 such as the Breast and Ovarian Analysis 
of Disease Incidence and Carrier Estimation Algo-
rithm (BOADICEA).10
Until now, the PRS is not included in clinical 
genetic practice to guide clinical management. 
Several studies have shown an improved discrim-
inative power between breast cancer cases and 
controls by combining the PRS with a breast cancer 
risk prediction tool.11–14 However, little is currently 
known of the discriminative power of the PRS 
between family members, with respect to who will 
develop breast cancer. A recent study genotyped 
cases and controls in 52 Finnish non-BRCA1/2 
breast cancer families to calculate a 75-SNP PRS. 
The PRS for healthy women from breast cancer 
families was lower in comparison with affected 
family members.15 This suggests that the PRS can 
help to individualise risk stratification and advice 
for surveillance for women in breast cancer families.
Here, we explore the clinical applicability of the 
161-SNP PRS for risk prediction in a cohort of 
101 high-risk breast cancer families not explained 
by pathogenic variants in the BRCA1 and BRCA2 
genes. The clinical impact of the PRS on breast 
cancer risk prediction based on family history 
alone was investigated by determining the potential 
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change in clinical management, as stipulated by three currently 
used guidelines (the National Comprehensive Cancer Network 
guideline (NCCN),16 the National Institute for Health and Care 
Excellence guideline (NICE)17 and the Netherlands Comprehen-
sive Cancer Organisation guideline (IKNL).18
MATerIAls And MeThods
study cohorts
Two cohorts were included, a hospital-based case–control 
(Oorsprong van borstkanker integraal onderzocht (ORIGO)) 
and a family-based case–control cohort. Informed consent was 
obtained for all individuals. Population controls were irrevers-
ibly anonymised. Only women were included in this study.
The ORIGO cohort consists of incident breast cancer cases, 
not selected for breast cancer family history enrolled between 
1996 and 2006 in the context of the ORIGO study, as described 
elsewhere.19 For the present study, 357 ORIGO cases were 
selected for which genotyping had been performed on the iCOGS 
array. Likewise, 327 healthy genotyped bloodbank donors were 
included in the ORIGO cohort as controls. Age of last follow-up 
was determined as the age at diagnosis for cases and the age at 
inclusion for controls.
The families from the family-based cohort were selected 
between 1990 and 2012 through five Clinical Genetic Services 
(Rotterdam, Groningen, Nijmegen, Leiden, the Netherlands, 
and Budapest, Hungary) and the Foundation for the Detec-
tion of Hereditary Tumours in the Netherlands, as previously 
described.20 At least one family member affected with breast 
cancer was tested for BRCA1 and BRCA2. We did not have 
informed consent for testing other specific genes besides BRCA1 
and BRCA2. The selection criteria for families included: breast 
cancer (invasive/in situ) before the age of 60 years in at least 
three women or in two women if at least one of them had 
bilateral breast cancer before the age of 60 years. In total, 102 
families without a pathogenic variant in BRCA1 or BRCA2 were 
included of which a blood DNA sample was available for 612 
women. Of these women, 340 were affected with breast cancer 
and 272 were unaffected relatives. The unaffected relatives were 
censored regarding breast cancer, irrespective of other types of 
cancer. Most cancers were verified with a pathology report. Date 
of last follow-up was determined as the date of last contact with 
the family.
Genotyping
DNA samples of all included individuals were genotyped with 
the iCOGS SNP array, designed for association analysis in breast, 
ovarian and prostate cancer, containing 211 155 SNPs.3 Geno-
typing and quality control of the ORIGO cohort was performed 
as part of association studies conducted by the Breast Cancer 
Association Consortium (BCAC).3 For the family-based cohort, 
quality control led to the exclusion of 27 individuals (see online 
supplementary material and methods). Therefore, further anal-
ysis was done with 323 breast cancer cases and 262 unaffected 
relatives from 101 families for this cohort.
Imputation
Some of the 182 currently known SNPs are associated primarily 
with oestrogen receptor (ER)-negative or ER-positive breast 
cancer. We constructed a PRS for overall breast cancer with 
161 SNPs, selecting all SNPs significantly associated (p<5.10−8) 
with overall breast cancer in case–control studies performed 
by BCAC4 (online supplementary table S1). ER status was not 
known for all cases in our study, and substrata would become 
too small to reach sufficient statistical power for ER-specific 
PRSs. The 85 SNPs that were not directly genotyped by the 
iCOGS array were imputed by prephasing with SHAPEIT and 
IMPUTE2.21 22 To improve imputation quality both the refer-
ence panels 1000 genomes phase three and Genome of the Neth-
erlands (GoNL) were used.23 24
Polygenic risk score









where nij is the number of risk alleles (0, 1 or 2) for SNP i 
carried by individual j and ORi is the per-allele log OR for breast 
cancer associated with SNP i. The ORs were the most recent 
estimates from analysis of the OncoArray data4 (online supple-
mentary table S1). The majority of studies used for this analysis 
were population-based case–control studies.4
The PRS was calculated for all included individuals. For the 
descriptive analysis, the PRS was standardised to the mean and 
SD in healthy population controls. The mean standardised PRS 
(sPRS) in population controls is therefore 0 with an SD of 1. 
Standardisation facilitates the comparison between different 
groups. For further analysis in the family-based cohort, the PRS 
was standardised to the mean and SD in the family-based cohort 
including both cases and unaffected relatives.
Total boAdICeA score and polygenic load (boAdICeAFh)
The pedigrees were collected and drawn for all families, 
including all known first-degree and second-degree relatives of 
the genotyped individuals. For 25 of the 561 family members 
affected with breast cancer, the age of breast cancer diagnosis 
was not known. For these affected family members, the age at 
diagnosis was assumed to equal the average age of developing 
breast cancer in the Netherlands (61 years), or the age at last 
follow-up if this was earlier.
Two different scores were calculated for all individuals in the 
family cohort by the online risk prediction tool BOADICEA,10 the 
total BOADICEA score and the polygenic load. The total BOAD-
ICEA score (hereafter termed BOADICEALTR) is a measure for 
lifetime breast cancer risk and incorporates BRCA1 and BRCA2 
status, age, birth cohort and a polygenic load. The polygenic load 
in the BOADICEA model is an estimated polygenetic component 
representing a large number of loci of small effect to capture the 
residual familial aggregation of breast cancer and is therefore a 
measure of the breast cancer family history.15 Calculation of the 
polygenic load is described previously by Muranen et al.15 To 
avoid confusion between the variables polygenic load and the 
PRS, the polygenic load is hereafter termed BOADICEAFH. The 
BOADICEALTR and BOADICEAFH were calculated by simulating 
an individual to be at an age of 1 year and unaffected (for cases), 
that is, lifetime risk at birth, given the family history.
statistical analysis
To define the degree of correlation between the sPRS and the 
BOADICEAFH, the Pearson correlation coefficient was calcu-
lated. A Cox-type random effect regression model was used to 
estimate the association between the sPRS and breast cancer, 























enet: first published as 10.1136/jm




3Lakeman IMM, et al. J Med Genet 2019;0:1–9. doi:10.1136/jmedgenet-2019-106072
Cancer genetics
Table 1 Characteristics of all included individuals




number 357 327 323 262
Age
  Mean (SD) 56 (10) 46 (14) 51 (11) 62 (17)
  Range 23–84 18–90 26–90 17–94
Country of origin
  The Netherlands 357 327 317 249
  Hungary – – 6 14
First breast tumour
  Invasive (%) 313 (88) – 317 (98) –
  DCIS (%) 32 (9) – 4 (1) –
  Unknown (%) 12 (3) – 2 (1) –
second breast tumour
  Invasive (%) 19 (5) – 51 (16) –
  DCIS (%) 2 (1) – 4 (1) –
  Unknown (%) 0 (0) – 5 (2) –
Family score
  BOADICEAFH (SD) – – 1.03 (0.40) 1.05 (0.39)
  BOADICEALTR (SD) – – 0.23 (0.07) 0.23 (0.06)
BOADICEAFH, Breast cancer family history score; BOADICEALTR, Breast cancer lifetime 
risk at age 80; DCIS, ductal carcinoma in situ.
where  tij  is the age at first diagnosis of breast cancer or the age 
at censoring for member j in family i. Censoring was done at age 
of last contact with the family or death. Censoring at the age of 





  refers to the baseline hazard, which is left completely 
unspecified (Cox-type model),  β1  is the main effect of interest, 
the regression coefficient of the sPRS and β2 is the effect of the 
BOADICEAFH. In comparing affected to unaffected relatives, it 
is important to adjust for different numbers of affected versus 
unaffected relatives per family. We therefore added a family 
specific random effect u>0 in our model, shared by the members 
of the same family. This unobserved heterogeneity shared within 
families was assumed to follow a gamma distribution.
To evaluate the potential of the sPRS on the reclassification 
of breast cancer risk, we constructed a new individual breast 
cancer risk score based on both the BOADICEALTR and the esti-
mated effect of the sPRS with the model defined by expression 
1. Namely, since BOADICEALTR is defined as the probability of 
experiencing breast cancer before age 80 years, the new score 
is calculated as the distribution function at 80 of a Cox propor-
tional hazard model using BOADICEALTR as baseline (average 
risk in the sample) and the sPRS as covariate:
 BOADICEAsPRS = 1− (1− BOADICEALTR)∧(e(β1 ∗ sPRS)) (2)
The sPRS is expected to individualise cancer risk estimates but 
not to alter the overall average risk level computed by BOAD-
ICEA in the joint sample, that is, the higher risks given to some 
individuals are expected to be compensated by lower risks in 
others. For this reason, we centred the sPRS at the mean of the 
whole family cohort.
The risk calculation based on BOADICEA alone (BOADICE-
ALTR) and the new individual breast cancer risk score (BOADI-
CEAsPRS) were compared for all individuals in the family-based 
cohort to define the change in risk category and thus advice for 
breast cancer surveillance according to three different guidelines, 
NICE,17 NCCN16 and IKNL18 (online supplementary table S2).
Statistical significance was established at 5%, analysis was 
performed using R V.3.4.1.25
resulTs
The analysis of the ORIGO cohort included 357 breast cancer 
cases and 327 population controls. The analysis of the fami-
ly-based cohort included 323 breast cancer cases and 262 unaf-
fected relatives from 101 families. Unaffected relatives derived 
from 49 of these 101 families.
descriptive analysis
Virtually all breast cancers were invasive in both cohorts, and 
second breast cancers were more prevalent in familial cases 
(table 1). In both the ORIGO and family-based cohort, the sPRS 
was on average higher in cases than in controls (table 2). The 
unaffected relatives in the family-based cohort had on average 
a higher sPRS in comparison with ORIGO cases and controls. 
The mean sPRS for sporadic cases was 0.35 (SD=0.92), and in 
the family-based cohort, the mean sPRS was 0.70 (SD=0.90) 
and 0.53 (SD=0.95) for the affected and unaffected relatives, 
respectively. In the family-based cohort, the sPRS was higher for 
cases with two invasive breast tumours in comparison with cases 
with one breast tumour (invasive/in situ), with a mean sPRS of 
0.66 (SD=0.89) and 0.89 (SD=0.93), respectively. The distribu-
tions of the sPRS in both cohorts are shown in figure 1. Infor-
mation about the 95% CI and SE in different groups are shown 
in table 2.
Correlation
Further analyses were performed only for the family-based 
cohort. A weak but statistically significant positive correlation 
was detected between the BOADICEAFH (measure of the family 
history) and the sPRS. The Pearson correlation coefficient was 
0.103, 95% CI 0.022 to 0.183, p=0.013, which means that 
1.1% of the variance in the sPRS is explained by the BOAD-
ICEAFH. Larger correlation was found in the unaffected rela-
tives (correlation coefficient 0.153, 95% CI 0.032 to 0.269, 
p=0.013). No evidence of correlation was found in family cases 
only (correlation coefficient 0.057, 95% CI −0.052 to 0.165, 
p=0.306).
Cox-type random effects modelling
The sPRS should not be directly combined with the BOADICE-
ALTR because the PRS is a part of the familial relative risk, captured 
by BOADICEA by its polygenic component, the BOADICEAFH. 
For this reason, adjustment was made by the BOADICEAFH in 
the association analysis, using the model defined by expression 
1. Furthermore, adjusting for the BOADICEAFH helps to correct 
for ascertainment bias. The BOADICEAFH was calculated for 
cases assuming they were at age 1 year and unaffected. Conse-
quently controls have, in our sample, a larger BOADICEAFH 
than cases. Hence, adding the BOADICEAFH as a covariate in 
the model indirectly corrects the oversampling of cases of our 
design. Within the family-based cohort, the sPRS was signifi-
cantly associated with breast cancer, conferring an HR of 1.16 
(95% CI 1.03 to 1.28; p=0.026) per SD. No statistical signifi-
cant association was found without adjustment, HR 1.10, 95% 
CI 0.98 to 1.23, p=0.122.
Prs-based individualised risk score
To calculate a PRS-based breast cancer risk score (BOADICEA-
sPRS), the individual sPRS was combined with the BOADICEALTR. 
Both risk scores for each individual in the family-based cohort 
are plotted against each other in figure 2. This resulted in a 
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Table 2 Descriptive analysis 161-SNP PRS
Group Mean sPrs sd sPrs se sPrs n 
95% CI
lower limit upper limit
Family breast cancer cases 0.70 0.90 0.05 323 0.60 0.80
  1 breast tumour 0.66 0.89 0.05 267 0.55 0.76
  2 breast tumours 0.89 0.93 0.12 56 0.65 1.13
Unaffected relatives 0.53 0.95 0.06 262 0.41 0.64
ORIGO cases 0.35 0.92 0.05 357 0.26 0.45
Population controls 0.00 1.00 0.06 327 −0.11 0.11
PRS, polygenic risk score; SNP, single nucleotide polymorphism; sPRS, standardised PRS.
Figure 1 Distribution of the standardised 161-SnP PrS. the standardised 161-SnP PrS was plotted against the density in the different cohorts. (a) 
incident breast cancer cases and population controls from the OrigO cohort; (B) population controls from the OrigO cohort, breast cancer cases and 
unaffected relatives from the family-based cohort; (c) population controls from the OrigO cohort, breast cancer cases with one and two primary breast 
tumours from the family-based cohort. PrS, polygenic risk score; SnP, single nucleotide polymorphism.
change in breast cancer lifetime risk for all individuals. We eval-
uated the proportions of individuals that would fall in another 
risk management category, given risk cut-off levels from three 
different clinical guidelines. Risk management changed for 
19.8%, 14.7% and 11.5% of women under the IKNL,18 NICE17 
and NCCN16 guidelines, respectively (table 3). The percentage 
of family cases and unaffected relatives who changed to a lower 
or higher risk category based on these guidelines are shown in 
online supplementary table S3. Examples of the change in breast 
cancer risk category are shown for individuals in three pedigrees 
in figure 3 and online supplementary table S4.
dIsCussIon
PRSs, derived from a combination of disease-associated SNPs, 
are gaining importance as predictive factor for a range of disease 
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Figure 2 change in breast cancer lifetime risk score. For every individual, 
BOaDiceasPrS was plotted against BOaDicealtr. the dotted lines represent 
the 17% breast cancer lifetime risk cut-off level. the solid lines represent 
the 20% and 30% breast cancer lifetime risk cut-off levels. BOaDiceasPrS, 
161-SnP PrS based breast cancer lifetime risk score; BOaDicealtr, breast 
cancer lifetime risk at age 80, based on BOaDicea alone.
Table 3 Breast cancer risk category change in the family-based cohort
lifetime risk IKnl18 nICe17 nCCn16
boAdICeAlTr boAdICeAsPrs n % change n % change n % change
<17% <17%     108 10.7     
<17% >17%     13     
17%–30% 17%–30%     317 15.5     
17%–30% <17%     24     
17%–30% >30%     34     
<20% <20% 175 14.2     175 14.2
<20% >20% 29     29
>20% >20%         343 10.0
>20% <20%         38
20%–30% 20%–30% 220 24.7         
20%–30% <20% 38         
20%–30% >30% 34         
>30% >30% 74 16.9 74 16.9     
>30% <30% 15 15     
overall change   19.8   14.7   11.5
Following the Dutch IKNL guideline, cut-off levels of 20% and 30% represent low, moderate and high risk categories. Following the NICE guideline, 17% and 30% represent low, 
moderate and high risk categories. Following the NCCN guideline, 20% represent a cut-off level for the high-risk category.
BOADICEALTR, breast cancer lifetime risk at age 80, based on BOADICEA alone; BOADICEAsPRS, 161-SNP PRS based breast cancer lifetime risk score; IKNL, Netherlands 
Comprehensive Cancer Organisation; NCCN, National Comprehensive Cancer Network; NICE, National Institute for Health and Care Excellence.
phenotypes, including breast cancer.26 All discovered breast 
cancer SNPs to date explain 18% of the familial relative risk.4 
Here, we use a PRS based on these SNPs to show the potential 
clinical utility within high-risk breast cancer families. While most 
studies use population controls as a reference group,2 8 12 13 we 
used the healthy relatives of breast cancer cases as a reference to 
make it more compatible with clinical practice in Family Cancer 
Clinics. Similar to population-based case–control studies,2 12 13 
we found that the PRS was significantly associated with breast 
cancer within high-risk breast cancer families. In addition, 
the PRS may change breast screening recommendations in a 
substantial proportion of women from these families, according 
to currently used screening guidelines.16–18 For incompleteness 
of data on ER status, we did not calculate PRSs predictive for 
ER-positive or ER-negative disease.5 27 While breast cancer 
screening guidelines are mainly based on overall breast cancer 
risk, some guidelines suggest discussing the use of chemopre-
vention with women at high risk of breast cancer.16 17 We expect 
these ER-specific PRSs, similar to the overall PRS, to individu-
alise these discussions within these families.
Some studies have described an association between the PRS 
and contralateral breast cancer.8 28 In agreement with this, we 
found the average sPRS in women diagnosed with two primary 
breast cancers in our family cohort to be higher in comparison 
with women with one breast cancer (similarly in ORIGO cases, 
online supplementary figure S1 and table S5). Thus, the PRS may 
be helpful managing contralateral breast cancer risk and guide 
the choice for treatment or risk reducing mastectomy.
The family-based cohort used in our study was not part of 
the cohort used to discover the breast cancer associated SNPs 
by GWAS, while the ORIGO cohort was.3 4 A notable finding in 
our family-based cohort was that unaffected relatives of familial 
breast cancer cases had on average a higher sPRS than ORIGO 
incident breast cancer cases, not selected by family history. This 
may be due to our selection of families with multiple cases of 
breast cancer, since SNPs of this PRS are expected to cluster 
in breast cancer families. Moreover, the mean sPRS we calcu-
lated for ORIGO cases was lower than found in a large popula-
tion-based study.2 Since we found no evidence for substructures 
in the ORIGO cohort (online supplementary figure S1 and table 
S5), this effect is probably due to the relatively small number of 
ORIGO cases included in this study.
Three previous studies have also genotyped breast cancer 
cases and their unaffected relatives.7 15 29 These studies found 
an association with breast cancer as well, but effect sizes are 
difficult to compare because of differences in methodology 
and cohort selection criteria. Furthermore, these studies used a 
much smaller number of SNPs to calculate the PRS. Li et al7 
analysed a prospective dataset and concluded that their 24-SNP 
PRS could have altered clinical management in up to 23% of 
women, regarding an MRI screening threshold of 20% breast 
cancer lifetime risk. Evans et al29 performed a case–control study 
of women attending a familial risk clinic and showed that their 
18-SNP PRS moved 52% of the controls without a pathogenic 
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Figure 3 risk management change for 11 women from three pedigrees. risk changes are based on the Dutch iKnl screening guideline18 (online 
supplementary table S2). an arrow indicates that a woman has been genotyped. generations in the pedigree are numbered with i, ii, iii and iV. Based on the 
individual BOaDiceasPrS score, 11 individuals will change to a higher (+) or lower (−) risk category compared with the BOaDicealtr score and will receive 
other breast screening surveillance. B, breast cancer; BOaDiceasPrS, 161-SnP PrS based breast cancer lifetime risk score; BOaDicealtr, breast cancer lifetime 
risk at age 80, based on BOaDicea alone; iKnl, netherlands comprehensive cancer Organisation.
variant in BRCA1 or BRCA2 to a different lifetime risk category 
based on the NICE guideline.17 29
In our study, we adopted a conditional approach for associ-
ation analysis because of the large heterogeneity between the 
families. Although our use of the BOADICEAFH adjusts for family 
history, the HR is probably still underestimated given the strong 
selection criteria used in our study. Of note, this BOADICEAFH is 
not a true family score in a clinical sense, given the retrospective 
nature of our family cohort. In clinical practice, the risk scores 
are only calculated for unaffected family members, while in this 
study, we derive the BOADICEAFH also for cases, assuming they 
were at age 1 year and unaffected. With this definition, controls 
have, in general, a larger BOADICEAFH than cases. Hence, 
adding the BOADICEAFH as a covariate in the model indirectly 
corrects the oversampling of cases of our design. The same defi-
nition of the BOADICEAFH is also used when computing BOAD-
ICEALTR and the new individual score BOADICEAsPRS, given by 
expression 2.
We found that 1.1% of the variance in the sPRS is explained 
by the BOADICEAFH. Given that 18% of the familial relative 
risk for breast cancer is explained by the currently known SNPs, 
this is lower than expected. Nonetheless, other studies have also 
found a weak correlation or no correlation at all between the 
PRS and the BOADICEAFH or total BOADICEA score.
12 15 Thus, 
BOADICEA appears to be a poor predictor of the PRS, under-
scoring the value of measuring the PRS for every individual in 
the family instead of using an estimated PRS based on the total 
family history.
It is estimated that a large number of SNPs just below the 
level of genome-wide significance, combined with the currently 
used 161 SNPs, are able to explain about 41% of the familial 
relative risk.4 Addition of these SNPs could potentially further 
refine risk prediction and improve the discriminatory power of 
the PRS. Studies are now ongoing to find the best performing 
PRS, including also these SNPs. Khera et al30 found that a PRS 
of 5218 SNPs associated with breast cancer at a significance level 
of <5.10−4, combined with age, had the best performance based 
on the area under the receiver-operator curve. Mavaddat et al31 
used a hard-thresholding approach to include 313 SNPs at a 
significance level of <10−5. A further improvement for breast 
cancer risk prediction could come from information on patho-
genic variants in non-BRCA high-risk or moderate-risk breast 
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cancer genes (eg, PALB2, CHEK2 and ATM). Pathogenic variants 
in these genes are found in approximately 4%–6% of women 
affected with breast cancer.32 33 Recently, the BOADICEA model 
has been extended with incorporation of the effects of truncating 
variants in CHEK2, PALB2 and ATM and the 313-SNP based 
PRS to calculate breast cancer lifetime risks.34 A limitation of our 
study is that we had no ethical approval to test CHEK2, PALB2 
and ATM in the studied families. Extrapolating from expected 
prevalences of pathogenic variants in these genes, we estimate 
the total percentage of individuals that would have changed 
to another risk category by addition of the PRS to be 3%–4% 
higher than the 20% we report here.
In summary, we showed that the PRS based on the most 
recently discovered breast cancer SNPs can be used for breast 
cancer risk prediction within high-risk breast cancer families. 
Individualising breast cancer risk prediction by adding the indi-
vidual 161-SNP PRS to family history-based risk prediction may 
change screening recommendation in up to 20% of the indi-
viduals in these families. While this study illustrates the impor-
tance of clinical applicability of the PRS, our results must be 
interpreted with caution. The HR obtained in this family cohort 
cannot be translated directly to the clinic as the effect size must 
be validated in another larger familial breast cancer cohort. 
Further evaluation, preferably in prospective settings, will be 
needed.
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